saxenda glp 1 agonist Saxenda® Saxenda: A Breakthrough Weight Loss
Description
Reports submitted to the FDA Adverse Event Reporting System have included insomnia, anxiety, nervousness, and depressive symptoms, 79 while the European Medicines Agency has flagged cases of depression, self-injury, and suicidal ideation among users of liraglutide or semaglutide
Front Endocrinol 11:178 Marso SP, Daniels GH, Brown-Frandsen K, et al (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
routine DOAC monitoring not standard | Frequently asked questions What is the GLP-1 receptor agonists drug class
PubMed, Ding, Weiyue, et al
Cell Rep 33:108271
